Biogen Inc. (BIIB)
Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise
Biogen cut its full-year adjusted-earnings expectations, though third-quarter profit rose on strength from its Alzheimer's drug and rare-disease treatments.
Biogen trims annual profit forecast on expected hit from R&D-related charges
Biogen cut its annual profit forecast on Thursday, as it expects to take a hit of $1.25 per share from R&D related charges tied to certain acquisitions in the fourth quarter.
Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?
Biogen's new drugs Leqembi, Skyclarys and Zurzuvae are driving fresh momentum, but MS and Spinraza declines cloud its growth path.
Biogen's Comeback: Why The Bulls Are Finally Winning Again
Mr. Market's bullish sentiment towards Biogen is returning. One reason for this is its strengthening position in the multiple sclerosis drugs market, thanks to Vumerity, whose sales reached $212.3 million in Q2 2025, up 28% year-on-year. Also, Biogen's EBIT margin has continued to grow over the past four quarters, reaching 34.6% for the three months ended June 30, 2025.
BIIB Stock: Is Biogen Still A Buy After The 14% Spike?
Biogen (BIIB) shares recorded their fifth consecutive day of increases, accumulating a total return of 14% during this span. The company's market value has increased by approximately $3.3 billion over the past 5 days, bringing its current market capitalization to around $23 billion.
Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Biogen Inc. (NASDAQ:BIIB ) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 11:20 AM EDT Company Participants Priya Singhal - Executive VP & Head of Development Conference Call Participants William Pickering - Sanford C. Bernstein & Co., LLC.
Biogen Gets EU Nod for First Postpartum Depression Drug
BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.
These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and More
Companies on the move in today's trading.
Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript
Biogen Inc. (NASDAQ:BIIB ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Alisha A. Alaimo - President & Head of North America Christopher A.
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates
Biogen Inc. (BIIB) came out with quarterly earnings of $5.47 per share, beating the Zacks Consensus Estimate of $3.93 per share. This compares to earnings of $5.28 per share a year ago.
